SCHEMBL11100764

SCHEMBL11100764

NC1(C(=O)O)CCc2ccc(O)cc2C1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.42
MAPT P10636 2/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP2C19 P33261 2/20 0.42
POLB P06746 1/20 0.42
BLM P54132 1/20 0.42
GRM1 Q13255 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MEN1 O00255 1/20 0.42
MAPK1 P28482 1/20 0.42
KMT2A Q03164 1/20 0.42
DRD2 P14416 1/20 0.40
DRD3 P35462 1/20 0.40
LMNA P02545 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP1A2 P05177 1/20 0.39
ALOX15 P16050 1/20 0.39
GRM2 Q14416 1/20 0.39
ESR1 P03372 3/20 0.38
ESR2 Q92731 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3060808 0.93 KDM4E (0.42) KDM4EMAPTALDH1A1CYP2C19POLB
Bromide SCHEMBL10913183 0.92 KDM4E (0.41) KDM4EMAPTALDH1A1CYP2C19POLB
SCHEMBL7277003 0.86 HSD17B1 (0.42) KDM4EMAPTALDH1A1POLBBLM
SCHEMBL16605573 0.84 KDM4E (0.40) KDM4EMAPTALDH1A1CYP2C19POLB
SCHEMBL24803566 0.81 KDM4E (0.38) KDM4EMAPTALDH1A1CYP2C19POLB
SCHEMBL30758546 0.81 KDM4E (0.38) KDM4EMAPTALDH1A1CYP2C19POLB
SCHEMBL29511535 0.81 PARP1 (0.39) KDM4EMAPTALDH1A1CYP2C19POLB
SCHEMBL199421 0.81 PARP1 (0.39) KDM4EMAPTALDH1A1CYP2C19POLB
SCHEMBL268919 0.81 PARP1 (0.39) KDM4EMAPTALDH1A1CYP2C19POLB
SCHEMBL29410824 0.81 PARP1 (0.39) KDM4EMAPTALDH1A1CYP2C19POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035339-A1 TETRAHYDRONAPHTHALENE DERIVATIVE ATRANSEN PHARMA LTD (JP) 2026-02-05 US disclosed
EP-4501906-A1 TETRAHYDRONAPHTHALENE DERIVATIVE Atransen Pharma Ltd. (JP) 2025-02-05 EP disclosed
CN-118974007-A Tetrahydronaphthalene derivatives 阿创森制药股份有限公司 2024-11-15 CN disclosed
WO-2023190878-A1 TETRAHYDRONAPHTHALENE DERIVATIVE Atransen Pharma株式会社 2023-10-05 WO disclosed
WO-2023190878-A1 TETRAHYDRONAPHTHALENE DERIVATIVE Atransen Pharma株式会社 2023-10-05 WO disclosed
US-4438103-A ANALGESIC OLIGOPEPTIDES SANDOZ LTD. (CH) 1984-03-20 US disclosed
US-4261888-A ANALGESIC OLIGOPEPTIDES SANDOZ LTD. (CH) 1981-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035339-A1 TETRAHYDRONAPHTHALENE DERIVATIVE LATS1, LATS2, BCAT1 KDM4E 3452/4885MAPT 905/4885ALDH1A1 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.